NCT06239636View on ClinicalTrials.gov

First-in-human Safety Study of Hypoimmune Pancreatic Islet Transplantation in Adult Subjects With Type 1 Diabetes

EARLY_PHASE1RecruitingINTERVENTIONAL

Enrollment

2

Participants

Timeline

Start Date

March 8, 2024

Primary Completion Date

May 31, 2025

Study Completion Date

June 30, 2025

Conditions

Type1diabetes

Interventions

BIOLOGICAL

UP421

Intramuscular transplantation with the ATMP UP421 composed of genetically modified human pancreatic islet cells

Trial Locations (1)

75185

RECRUITING

Uppsala University Hospital, Uppsala

Sponsors

Collaborators (1)

Sana Biotechnology

All Listed Sponsors

collaborator

Sana Biotechnology

INDUSTRY

lead

Per-Ola Carlsson

OTHER